| Schedule of Segment Information |
Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit. | | | Three Months Ending | | | | | April 30, | | | | | 2026 | | | 2025 | | | Net Sales | | | | | | | | Pocono Pharmaceuticals | | $ | 433,399 | | | $ | 667,432 | | | 4P Therapeutics | | | - | | | | - | | | Total | | | 433,399 | | | | 667,432 | | | Gross Profit | | | | | | | | | | Pocono Pharmaceuticals | | | 196,801 | | | | 251,981 | | | 4P Therapeutics | | | - | | | | - | | | Total | | | 196,801 | | | | 251,981 | | | | | | | | | | | | | Operating Expense | | | | | | | | | | Selling, general and administrative - Pocono Pharmaceuticals | | | 156,788 | | | | 151,528 | | | Selling, general and administrative - 4P Therapeutics | | | 6,483 | | | | 19,999 | | | Selling, general and administrative - Corporate | | | 1,049,734 | | | | 810,525 | | | Goodwill and intangibles impairment | | | - | | | | - | | | Research and development - 4P Therapeutics | | | 238,229 | | | | 683,426 | | | Total | | | 1,451,234 | | | | 1,665,478 | | | | | | | | | | | | | Depreciation and Amortization | | | | | | | | | | Pocono Pharmaceuticals | | $ | 24,910 | | | $ | 42,813 | | | Corporate | | | - | | | | - | | | 4P Therapeutics | | | 9,267 | | | | 9,267 | | | Total | | $ | 34,177 | | | $ | 57,480 | |
|
| Schedule of Information about Net Sales and Property and Equipment |
The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere. | | | Three Months Ending | | | | | April 30, | | | | | 2026 | | | 2025 | | | Net Sales | | | | | | | | United States | | $ | 433,399 | | | $ | 667,432 | | | Outside the United States | | | - | | | | - | | | Total | | $ | 433,399 | | | $ | 667,432 | | | Property and equipment, not of accumulated depreciation | | April 30, 2026 | | | January 31, 2026 | | | United States | | $ | 548,244 | | | $ | 567,255 | | | Outside of the United States | | | - | | | | - | | | Total | | $ | 548,244 | | | $ | 567,255 | | | | | | | | | | | | | Assets | | | | | | | | | | Corporate | | $ | 3,818,051 | | | $ | 4,437,703 | | | Pocono Pharmaceuticals | | | 1,825,258 | | | | 1,820,731 | | | 4P Therapeutics | | | 1,248,993 | | | | 1,294,501 | | | Total | | $ | 6,892,302 | | | $ | 7,547,935 | |
|